Study of Anticoagulants low molecular weight heparin and Unfractionated heparin in the management of Non-St elevation Myocardial Infarction. Research J. Pharm. and Tech. 2020
ABSTRACT: Introduction: MI is the leading cause of adult death in the United States (US). It is the predominant cause and responsible for more than 80% of CVD deaths in India. Objective: The objective of this study is to compare the effectiveness, adverse effects, mortality and safety profile of two anti-coagulants (LMWH & UFH) in the patients of acute coronary syndrome (NSTEMI). Methodology: A prospective observation study conducted on 70 adult patients at Durgabhai Deshmukh Hospital and Research Centre, Hyderabad on patients admitted for elective surgery for a period of six months. Results: Among 70 patients 56(80%) are males and 14 (20%) are females. Among all age groups major numbers of NSTEMI patients are seen in 51-60 years (30%). Among all patients 56 out of 70 patients i.e., 80% are with chest pain as chief complaint, 19 patients i.e., 27% are with sweating as chief complaint, 21 patients are with shortness of breath (SOB) as chief complaint i.e., 30% and 9 patients are with palpitations as chief complaint i.e., 13%. Among all patients 8 out of 70 patients suffered gastric bleeding i.e., 11.4% and 1 out of 70 patients suffered from intracranial bleeding i.e., 1.42%.Among all patients 9 patients out of 70 suffered with heart failure i.e., 12.85%, 22 patients out of 70 suffered with tachyarrhythmia i.e., 31.4%, and 13 patients suffered local bleeding i.e., 18.57%. Conclusion: From the study it is concluded that, patients with NSTEMI are given both the regimens i.e., low molecular weight heparin and un fractionated heparin and found that 27% more risk is observed in regimen 2 i.e., un fractionated heparin until the limited follow up that has done. KEYWORDS: Anticoagulants, Unfractionated heparin, Myocardial Infarction.
Files not available for this dataset
This contains only metadata